Business Context and Reporting Period
This Form 6-K filing by BioBlast Pharma Ltd. (not Enlivex Ltd.) covers the month of December 2017. The report details the results of the Annual and Extraordinary General Meeting of Shareholders held on December 21, 2017.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance actions taken at the shareholder meeting.
Material Changes
- Shareholder Approvals: Shareholders approved all agenda items as originally proposed in the November 16, 2017, Form 6-K.
- Correction of Option Grant: An error regarding a stock option grant to Mr. Robert Friedman was corrected. The original proposal for 30,000 shares failed to account for a 5-to-1 reverse split effected on September 18, 2017.
- Amended Grant: The shareholders approved an amended grant of options to purchase 6,000 ordinary shares (0.05 NIS par value) instead of the originally proposed 30,000 shares (0.01 NIS par value).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies. The document serves as a procedural record of the shareholder meeting outcomes.
Investor Verification Checklist
- Verify the impact of the 5-to-1 reverse split on outstanding share counts and option valuations.
- Confirm the final terms of the stock option grant to Mr. Robert Friedman (6,000 shares).
- Review the full agenda items referenced in Exhibit 99.1 of the November 16, 2017, Form 6-K for details on other approved resolutions.